Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
Ling Lin1 ,* Xiaomai Wu1 ,* Shuangquan Yan,1 Yefei Zhu,1 Zhengqing Yan,2 Dongqing Lv,1 Hongfei Ge3 1Department of Respiratory Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, People’s Republic of China; 2The Medical Department, 3D Medicines Inc., Shanghai, People&rsqu...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/response-to-afatinib-in-a-patient-with-nsclc-harboring-novel-egfr-exon-peer-reviewed-article-OTT |
id |
doaj-e8f0d4fa192a424e98580bfb9a841079 |
---|---|
record_format |
Article |
spelling |
doaj-e8f0d4fa192a424e98580bfb9a8410792020-11-25T03:43:03ZengDove Medical PressOncoTargets and Therapy1178-69302020-09-01Volume 139753975757588Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion MutationsLin LWu XYan SZhu YYan ZLv DGe HLing Lin1 ,* Xiaomai Wu1 ,* Shuangquan Yan,1 Yefei Zhu,1 Zhengqing Yan,2 Dongqing Lv,1 Hongfei Ge3 1Department of Respiratory Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, People’s Republic of China; 2The Medical Department, 3D Medicines Inc., Shanghai, People’s Republic of China; 3Department of Thoracic Surgery, Taizhou Hospital of Wenzhou Medical University, Taizhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Dongqing Lv; Hongfei Ge Email Lvdq@enzemed.com; gehf@enzemed.comPurpose: Most epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are resistant to tyrosine kinase inhibitors (TKIs). While some non-small cell lung cancer (NSCLC) patients harboring special subtypes of EGFR ex20ins still achieved clinical response after TKIs treatment, identifying special subtypes of EGFR ex20ins is helpful to find out NSCLC patients who can respond to TKIs.Case Presentation: A 71-year-old non-smoker Chinese female was diagnosed with advanced lung adenocarcinoma harboring EGFR ex20ins (N771delinsKG). The patient received first-line afatinib (40 mg/day) therapy and a significant and substantial reduction in tumor size was observed subsequently. According to RESIST 1.1, a radiological partial response was achieved. The final progression-free survival was 10 months.Conclusion: This is the first published case report of EGFR N771delinsKG lung adenocarcinoma, which highlighted the heterogeneity of clinical response to TKIs for EGFR ex20ins-mutant NSCLC. Such results need to be further investigated in prospective studies.Keywords: afatinib, lung adenocarcinoma, EGFR exon 20 insertions, next generation sequencinghttps://www.dovepress.com/response-to-afatinib-in-a-patient-with-nsclc-harboring-novel-egfr-exon-peer-reviewed-article-OTTafatiniblung adenocarcinomaegfr exon 20 insertionsnext generation sequencing |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lin L Wu X Yan S Zhu Y Yan Z Lv D Ge H |
spellingShingle |
Lin L Wu X Yan S Zhu Y Yan Z Lv D Ge H Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations OncoTargets and Therapy afatinib lung adenocarcinoma egfr exon 20 insertions next generation sequencing |
author_facet |
Lin L Wu X Yan S Zhu Y Yan Z Lv D Ge H |
author_sort |
Lin L |
title |
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations |
title_short |
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations |
title_full |
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations |
title_fullStr |
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations |
title_full_unstemmed |
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations |
title_sort |
response to afatinib in a patient with nsclc harboring novel egfr exon 20 insertion mutations |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2020-09-01 |
description |
Ling Lin1 ,* Xiaomai Wu1 ,* Shuangquan Yan,1 Yefei Zhu,1 Zhengqing Yan,2 Dongqing Lv,1 Hongfei Ge3 1Department of Respiratory Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, People’s Republic of China; 2The Medical Department, 3D Medicines Inc., Shanghai, People’s Republic of China; 3Department of Thoracic Surgery, Taizhou Hospital of Wenzhou Medical University, Taizhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Dongqing Lv; Hongfei Ge Email Lvdq@enzemed.com; gehf@enzemed.comPurpose: Most epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are resistant to tyrosine kinase inhibitors (TKIs). While some non-small cell lung cancer (NSCLC) patients harboring special subtypes of EGFR ex20ins still achieved clinical response after TKIs treatment, identifying special subtypes of EGFR ex20ins is helpful to find out NSCLC patients who can respond to TKIs.Case Presentation: A 71-year-old non-smoker Chinese female was diagnosed with advanced lung adenocarcinoma harboring EGFR ex20ins (N771delinsKG). The patient received first-line afatinib (40 mg/day) therapy and a significant and substantial reduction in tumor size was observed subsequently. According to RESIST 1.1, a radiological partial response was achieved. The final progression-free survival was 10 months.Conclusion: This is the first published case report of EGFR N771delinsKG lung adenocarcinoma, which highlighted the heterogeneity of clinical response to TKIs for EGFR ex20ins-mutant NSCLC. Such results need to be further investigated in prospective studies.Keywords: afatinib, lung adenocarcinoma, EGFR exon 20 insertions, next generation sequencing |
topic |
afatinib lung adenocarcinoma egfr exon 20 insertions next generation sequencing |
url |
https://www.dovepress.com/response-to-afatinib-in-a-patient-with-nsclc-harboring-novel-egfr-exon-peer-reviewed-article-OTT |
work_keys_str_mv |
AT linl responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations AT wux responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations AT yans responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations AT zhuy responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations AT yanz responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations AT lvd responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations AT geh responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations |
_version_ |
1724521639662583808 |